Search results
Results From The WOW.Com Content Network
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), [citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors ().
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
What links here; Related changes; Upload file; Special pages; Permanent link; Page information; Get shortened URL; Download QR code
The natural somatostatin receptor ligand, the 14 amino acid peptide somatostatin (A), was abridged to the biologically more stable 8 amino acid peptide Octreotide (OC, B). Introduction of a tyrosine into the 3rd position of the Octreotide sequence resulted in Tyr3-Octreotide (TOC, C), which allows for iodination of the tyrosine residue with the ...
68 Ga DOTA-TATE (gallium-68 dotatate, GaTate) is used to measure tumor SSR density and whole-body bio-distribution via PET imaging. [11] [12] 68 Ga DOTA-TATE imagery has a much higher sensitivity and resolution compared to 111 In octreotide gamma camera or SPECT scans, due to intrinsic modality differences. [11]
Participants were randomly assigned to receive either 177 Lu dotatate with long-acting octreotide or long-acting octreotide, at a higher dose, alone. [15] 177 Lu dotatate was injected through the vein and long-acting octreotide was injected in the muscle. [15] Both, participants and health care providers knew which treatment was given. [15]
Some agonists were already approved by the FDA for clinical use, such as In-DTPA-octreotide and Ga-DOTATATE. [4] Development started after the discovery of modifications that can be done to the octreotide group, a ssrt selective subtype agonist, to cause its agonistic effects to be lost and gain antagonistic effects. [ 8 ]
Long-acting somatostatin analogues, octreotide LAR (administrated intramuscularly) and lanreotide (administered as a deep subcutaneous injection), are a convenient option for older children. An alternative treatment approach for diazoxide-unresponsive cases that are either not eligible or unresponsive to somatostatin analogues is the use of a ...